Xlife Sciences Net Income Applicable To Common Shares Over Time
| XLS Stock | 22.70 1.50 7.08% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Xlife Sciences Performance and Xlife Sciences Correlation. Xlife |
Cross Equities Net Income Applicable To Common Shares Analysis
Compare Xlife Sciences AG and related stocks such as VP Bank AG, St Galler Kantonalbank, and Cembra Money Bank Net Income Applicable To Common Shares Over Time
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VPBN | 20 M | 20 M | 20 M | 20 M | 20 M | 64.1 M | 58 M | 65.8 M | 54.7 M | 73.5 M | 41.6 M | 50.6 M | 40.2 M | 44.2 M | 18.5 M | 16.6 M | 15.8 M |
| SGKN | 146.3 M | 146.3 M | 146.3 M | 146.3 M | 146.3 M | 133.4 M | 146 M | 156 M | 158.6 M | 163.9 M | 167.2 M | 181.2 M | 183.8 M | 207.2 M | 215.1 M | 227 M | 191.2 M |
| CMBN | 139.8 M | 139.8 M | 139.8 M | 139.8 M | 139.8 M | 145 M | 143.7 M | 144.5 M | 154.1 M | 159.2 M | 152.9 M | 161.5 M | 169.3 M | 158 M | 170.4 M | 179.6 M | 172.2 M |
| LOGN | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 119.3 M | 205.9 M | 208.5 M | 257.6 M | 449.7 M | 947.3 M | 644.5 M | 364.6 M | 612.1 M | 631.5 M | 726.3 M | 445 M |
| METN | 86 M | 86 M | 86 M | 86 M | 86 M | 56.9 M | 84.9 M | 67.7 M | 63.6 M | 29.2 M | 14.3 M | 48.8 M | 130 M | 21.6 M | 52.6 M | 47.3 M | 47.7 M |
| BSKP | 93.5 M | 93.5 M | 93.5 M | 93.5 M | 93.5 M | 109 M | 121.7 M | 150.8 M | 190 M | 111.8 M | 108.3 M | 121.1 M | 139.3 M | 169.4 M | 186.3 M | 214.3 M | 150.1 M |
| BLKB | 115.8 M | 115.8 M | 115.8 M | 115.8 M | 115.8 M | 130.4 M | 133.6 M | 133.3 M | 134.5 M | 136.8 M | 138.1 M | 140.8 M | 130.2 M | 221.2 M | 207.5 M | 238.7 M | 162.2 M |
| ZUGER | 61.5 M | 61.5 M | 61.5 M | 61.5 M | 61.5 M | 61.5 M | 61.5 M | 68 M | 74.7 M | 74.7 M | 74.8 M | 75.3 M | 97.2 M | 124.8 M | 122.4 M | 131.1 M | 96.6 M |
Xlife Sciences AG and related stocks such as VP Bank AG, St Galler Kantonalbank, and Cembra Money Bank Net Income Applicable To Common Shares description
The net income that remains after preferred dividends have been deducted, available to common shareholders.My Equities
My Current Equities and Potential Positions
| Xlife Sciences AG | XLS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Talacker 35, Zurich, |
| Exchange | SIX Swiss Exchange |
null 22.7
Additional Tools for Xlife Stock Analysis
When running Xlife Sciences' price analysis, check to measure Xlife Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xlife Sciences is operating at the current time. Most of Xlife Sciences' value examination focuses on studying past and present price action to predict the probability of Xlife Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xlife Sciences' price. Additionally, you may evaluate how the addition of Xlife Sciences to your portfolios can decrease your overall portfolio volatility.